4.5 Review

Gut hormones: the future of obesity treatment?

期刊

BRITISH JOURNAL OF CLINICAL PHARMACOLOGY
卷 74, 期 6, 页码 911-919

出版社

WILEY
DOI: 10.1111/j.1365-2125.2012.04278.x

关键词

glucagon-like peptide-1; gut hormones; obesity; oxyntomodulin; pancreatic polypeptide; peptide YY

资金

  1. BBSRC [BB/I001816/1, BB/E52708X/1] Funding Source: UKRI
  2. Biotechnology and Biological Sciences Research Council [BB/I001816/1, BB/E52708X/1] Funding Source: Medline
  3. Biotechnology and Biological Sciences Research Council [BB/E52708X/1, BB/I001816/1] Funding Source: researchfish

向作者/读者索取更多资源

Obesity is a major worldwide health problem. The treatment options are severely limited. The development of novel anti-obesity drugs is fraught with efficacy and safety issues. Consequently, several investigational anti-obesity drugs have failed to gain marketing approval in recent years. Anorectic gut hormones offer a potentially safe and viable option for the treatment of obesity. The prospective utility of gut hormones has improved drastically in recent years with the development of longer acting analogues. Additionally, specific combinations of gut hormones have been demonstrated to have additive anorectic effects. This article reviews the current stage of anti-obesity drugs in development, focusing on gut hormone-based therapies.

作者

我是这篇论文的作者
点击您的名字以认领此论文并将其添加到您的个人资料中。

评论

主要评分

4.5
评分不足

次要评分

新颖性
-
重要性
-
科学严谨性
-
评价这篇论文

推荐

暂无数据
暂无数据